Press Room
  Date Title View
Sep 26, 2016
FOSTER CITY, Calif., Sept. 26, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced two important achievements in advancing the Company's clinical pipeline and development portfolio in Greater China. The first patient has been treated in the Phase 3 trial of ZADAXIN® in sepsis, a life-threatening infectious diseas...
PDF
Sep 12, 2016
PRINCETON, N.J. and FOSTER CITY, Calif., Sept. 12, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, and SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN), a US-based China-focused specialty pharmaceut...
PDF
Sep 1, 2016
FOSTER CITY, Calif., Sept. 1, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that the Company will present a corporate overview and business update at two investor conferences in September 2016. Friedhelm Blobel, PhD, Chief Executive Officer, will present at the Rodman & Renshaw 18th Annual Global ...
PDF
Aug 9, 2016
FOSTER CITY, Calif., Aug. 9, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter ended June 30, 2016.   Revenues: In the second quarter of 2016, SciClone reported revenues of $39.0 million, compared to $37.9 million for the same period in 2015. GAAP Diluted EP...
PDF
Jul 28, 2016
FOSTER CITY, Calif., July 28, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the second quarter 2016 on Tuesday, August 9, 2016. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET (1:30 pm PT) that day. The call wil...
PDF
Jul 19, 2016
FOSTER CITY, Calif., July 19, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today provided an update on part of the strategic review process that was previously announced in February 2016. The Company announced that it is no longer continuing active discussions with potential acquirers which were undertaken as part of its strat...
PDF
May 10, 2016
FOSTER CITY, Calif., May 10, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter ended March 31, 2016. Revenues: In the first quarter 2016, SciClone reported revenues of $36.5 million, compared to $33.6 million for the same period in 2015. GAAP Diluted EPS: In the fi...
PDF
Apr 25, 2016
FOSTER CITY, Calif., April 25, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the first quarter 2016 on Tuesday, May 10, 2016. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET (5:30 am PT) that day. The call will ...
PDF
Mar 30, 2016
FOSTER CITY, Calif., March 30, 2016 /PRNewswire/-- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the 15th Annual Needham Healthcare Conference at 8:00 am ET on Wednesday, April 13, 2016, at the Westin Grand Central Hotel in New Y...
PDF
Mar 10, 2016
FOSTER CITY, Calif., March 10, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter and year ended December 31, 2015. Revenues: Revenues for the full year 2015 were $157.3 million, compared to $134.8 million for the full year of 2014. In the fourth quarter of 2015, revenues w...
PDF
FirstPrevious
2
...
NextLast